论文部分内容阅读
对氨茶碱不同给药方案进行血药浓度监测，为临床合理用药提供依据。方法：采用ＨＰＬＣ法测定血中不同时间的茶碱浓度，１０２例患者氨茶碱的给药方案分为口服组，静脉滴注组，静脉滴注＋口服组。结果：（１）口服０．２ｇ，ｑ８ｈ，或０．２ｇｔｉｄ的患者血药谷峰浓度在１０～２０μｇ·ｍｌ－１范围分别约占８７％和６５％。（２）静脉滴注０．５ｇ，ｑｄ，或静脉滴注０．２５ｇ，ｑｄ＋口服０．１ｇ，ｔｉｄ的患者血药谷峰浓度在１０～２０μｇ·ｍｌ－１范围分别约占７８％和８２％。（３）口服０．１ｇ，ｔｉｄ或０．２ｇ，ｑｎ的患者血药谷浓度＜１０μｇ·ｍｌ－１，分别约占９３％和８２％。３例发生毒性反应血药浓度均＞２０μｇ·ｍｌ－１。结论：对轻、中度哮喘的治疗和预防应使用较小剂量（０．１ｇ，ｔｉｄ或０．２ｇ，ｑｎ），维持血药浓度在５～１０μｇ·ｍｌ－１即可。
Aminophylline different drug regimens for blood drug concentration monitoring, to provide the basis for clinical rational use of drugs. Methods: Theophylline concentration was determined by HPLC at different times in blood. The schedule of aminophylline in 102 patients was divided into oral group, intravenous drip group and intravenous drip + oral group. Results: (1) The peak plasma concentration of cerebrospinal fluid (0.2g, q8h, or 0.2gtid) in oral administration was about 87% and 65% in the range of 10 ~ 20μg · ml-1. (2) In the range of 10 ~ 20μg · ml-1, 0.5g, qd, or intravenous drip 0.25g, qd + oral 0.1g, tid respectively accounted for 78% 82%. (3) Oral 0.1g, tid or 0.2g, qn in patients with plasma trough concentration <10μg · ml-1, accounting for about 93% and 82%, respectively. 3 cases of toxic reaction occurred in plasma concentrations were> 20μg · ml-1. Conclusions: For the treatment and prevention of mild and moderate asthma, the lower dosage (0.1g, tid or 0.2g, qn) should be used to maintain the plasma concentration of 5 ~ 10μg · ml-1.